CN100340246C - Globefish oil preparation and its preparing method - Google Patents
Globefish oil preparation and its preparing method Download PDFInfo
- Publication number
- CN100340246C CN100340246C CNB2004101039096A CN200410103909A CN100340246C CN 100340246 C CN100340246 C CN 100340246C CN B2004101039096 A CNB2004101039096 A CN B2004101039096A CN 200410103909 A CN200410103909 A CN 200410103909A CN 100340246 C CN100340246 C CN 100340246C
- Authority
- CN
- China
- Prior art keywords
- oil
- preparation
- globefish
- liver
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 64
- 241001627955 Tetraodon lineatus Species 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000003960 organic solvent Substances 0.000 claims abstract description 14
- 150000003863 ammonium salts Chemical class 0.000 claims abstract description 7
- 239000003381 stabilizer Substances 0.000 claims abstract description 7
- 210000004185 liver Anatomy 0.000 claims description 54
- 238000003756 stirring Methods 0.000 claims description 17
- 239000012043 crude product Substances 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 238000006297 dehydration reaction Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 210000001672 ovary Anatomy 0.000 claims description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 6
- 230000018044 dehydration Effects 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 5
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 4
- 239000001099 ammonium carbonate Substances 0.000 claims description 4
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 3
- JIMMWYQEWFKFKI-UHFFFAOYSA-N C1(=CC=CC=C1)O.C1(=CC=CC=C1)O.C(C)(C)(C)C1=CC=CC=C1 Chemical compound C1(=CC=CC=C1)O.C1(=CC=CC=C1)O.C(C)(C)(C)C1=CC=CC=C1 JIMMWYQEWFKFKI-UHFFFAOYSA-N 0.000 claims description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 3
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 229940075579 propyl gallate Drugs 0.000 claims description 3
- 235000010388 propyl gallate Nutrition 0.000 claims description 3
- 239000000473 propyl gallate Substances 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- 239000000908 ammonium hydroxide Substances 0.000 claims description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 2
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 31
- 229940079593 drug Drugs 0.000 abstract description 19
- 230000036407 pain Effects 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 9
- 210000001835 viscera Anatomy 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 4
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 abstract description 3
- 229950010357 tetrodotoxin Drugs 0.000 abstract description 3
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000839 emulsion Substances 0.000 abstract description 2
- 239000007901 soft capsule Substances 0.000 abstract description 2
- 239000000829 suppository Substances 0.000 abstract description 2
- 239000003513 alkali Substances 0.000 abstract 1
- 150000001447 alkali salts Chemical class 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 235000015961 tonic Nutrition 0.000 abstract 1
- 230000001256 tonic effect Effects 0.000 abstract 1
- 229960000716 tonics Drugs 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 129
- 235000019198 oils Nutrition 0.000 description 129
- 239000000872 buffer Substances 0.000 description 51
- 230000000202 analgesic effect Effects 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 19
- 241000251468 Actinopterygii Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 241001441723 Takifugu Species 0.000 description 6
- 230000036592 analgesia Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000007096 poisonous effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000002893 slag Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 241001441722 Takifugu rubripes Species 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 241000723353 Chrysanthemum Species 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241001222097 Xenocypris argentea Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241000736029 Ruvettus pretiosus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710138194 Spanin, outer lipoprotein subunit Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 241000054452 Takifugu ocellatus Species 0.000 description 1
- 241001441724 Tetraodontidae Species 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000915 fish venom Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 231100000731 ichthyotoxin Toxicity 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention discloses a globefish oil preparation with the main effective component of tetrodotoxin (TTX). The globefish oil preparation can be prepared into soft capsules, emulsion, nutrient tonics or suppository according to a conventional medicine preparation process for relieving pain or abstaining drug dependency. The present invention also discloses a preparation method of the preparation. The preparation method comprises the steps that the internal organs of globefish are homogenized, heated by adding water, and hydrolyzed by adding weak alkali and ammonium salt respectively to separate out globefish oil; the globefish oil is washed with water and is mixed with an organic solvent; after being crystallized at low temperature, the mixture is centrifugally filtered; after the organic solvent is removed from the filtered globefish oil, a proper amount of stabilizing agent is added, and then the globefish oil preparation is obtained. The preparation method has the advantages of simple technology, easy operation, high oil yield and stable quality.
Description
Technical field
The present invention relates to a kind of globefish oil preparation and preparation method thereof, specifically, the present invention relates to extract the internal organs such as a kind of liver, ovary the preparation method of puffer oil and globefish oil preparation thereof from the puffer fish.
Background technology
The puffer fish is a kind of edible Fish of condition that contain severe toxicity, is the poisonous fishes of forbidding the pin aquatic foods on the market in China.The nearly kind more than 40 of known whole world puffer fish mainly is distributed in marine sites such as coastal area of china, the sea of Japan and the Indian Ocean of west of pacific ocean and Mediterranean, and the puffer fish also has artificial cultivation at present, and wherein, Chinese puffer fish crop accounts for 70% of world wide production.In the Far East Area, puffer is regarded as a kind of delicious food since ancient times, according to surveying and determination, contains protein 18.7% in the puffer meat, fat 0.26%, vitamin B
1Be 0.2PPM, B
2Be 1PPM.The puffer fish internal organs has very high physiologically active, and therefore, puffer is again a kind of marine pharmaceutical resource of preciousness.
Puffer is poisonous but can be medicinal, and ancient books doctor work has record more, as Compendium of Material Medica " ichthyotoxin the most very " is just arranged, the record of " liver and seed are very toxic, can cure mainly the copperworm scar "; " Kaibao Bencao " has the record of " main tonify deficiency, the gas that dries, reason waist foot, remove haemorrhoids, parasite killing ".Abroad, ancient Assyrian, Babylonian know that also " ball fish " is the puffer fish, and be poisonous, can cure the disease.This shows that the puffer fish is medicinal existing long and historical widely.The puffer fish is out of favour because of the toxic people of making fears, so, how the puffer fish is used, turn harm into good, improve its economic worth, paid close attention to by many scholars.At home, the fifties just the someone begin puffer liver oil industrial utilization and edible research (1958, aquatic science technological achievement compilation. " comprehensive utilization of puffer ", Shanghai science tech publishing house, IV-46～56); The scholar that the sixties have specially to the liver oil of worm stricture of vagina Fugu and Fugu rubripes (Temmincket Schlegel) liver oil carry out medical test (Hou Wenpu. west of pacific ocean fishery proceeding, P40-45,1962; High brightness. marine drug research paper collection, Qingdao City's medical science institute, P55-61,1979); The seventies has the people that the puffer liver oil is made new oil generation, be used for clinical tumor test (Wu Hanlin. Chinese poisonous fishes and medicinal fishes, P274,1977); The seventies is to the eighties, and Hebei Provincial Aquatic Products Research Institute etc. develop " removing malicious puffer liver oil " (.1983 such as Wei Jiying, marine drug, 2:85～88 of effects such as significantly pressing down cancer, analgesia, antiinflammatory, enhancing human body immunity function; .1988 such as Hou Junge, 1-2:55～56; .1987 such as Cai Xiande, 2:14～16; .1984 such as Jiang Yun, marine drug, 4:33～35; Shu Ronghua .1985,3:7～9), still, because the effective ingredient of " removing malicious puffer liver oil " is unclear, the result fails to obtain the national drug application for registration, and gives up the study of; The high reputation of Japanese tail man " medicine for external use that effluent Puffer liver oil is made " applying date this patent (clear 94317) in 1980; Wang Weiguos in 1997 etc. have applied for that (CN1193516A, CN1279957A), still, this patent does not have the effective ingredient of clear and definite puffer liver oil drug rehabilitation for the drug rehabilitation patent of puffer liver oil.
Above-mentioned achievement and patent are prepared removes malicious puffer liver oil, has two big shortcomings: the one, and, the active ingredient of puffer liver oil is unclear, is difficult to the stable curative effect and the drug safety of assurance medicine; The 2nd,, with decocting in water or the dirty extraction liver oil of lamp baked liver and traditional freezing stearic method of removing, exist oil yield low, quality problems such as precipitate appear after the puffer liver oil is deposited easily.
In order to solve an above-mentioned difficult problem, we have carried out various analyses and research, with a kind of opposite thinking, we find that tetraodontoxin has special dose-effect relationship, be that tetraodontoxin is in certain dilution intervals, there is not drug treatment function, and in specific dilution intervals, have good withdrawal drug dependence effect (Huang Zhiqiang appoints thunderous etc. Chinese patent ZL98102072.0), in view of the above, infer the active ingredient or the component of puffer liver oil, be two or more than, wherein, drug rehabilitation and analgesic effective ingredient, supposition are residual micro-tetraodontoxins in " removing malicious puffer liver oil ".In order to guarantee drug safety, must clear and definite puffer oil effective ingredient and research improves the quality and the preparation method of oil yield.
Summary of the invention
Purpose of the present invention is to provide a kind of analgesia, drug rehabilitation determined curative effect, and effective ingredient is clear, safely, do not have an addicted globefish oil preparation.
The invention provides a kind of globefish oil preparation, it is characterized in that, the effective ingredient of described globefish oil preparation is a tetraodontoxin.
Described globefish oil preparation is puffer liver oil preparation or globefish ovary oil formulation; The concentration of tetraodontoxin is 0.01 μ g/ml～15 μ g/ml in the described globefish oil preparation.
Another purpose of the present invention is, provides a kind of technology simple, implements oil yield height, the preparation method of stay-in-grade globefish oil preparation easily.
The preparation method of described above-mentioned globefish oil preparation is characterized in that,
(1) with homogenate after the globefish liver stripping and slicing, add 0.5～3 times of water in the liver weight ratio, be heated to 30～60 ℃ after, regulate pH value to 7～10, reheat to 60～90 ℃ are incubated 20～60 minutes, add 5%～20% ammonium salt by weight proportion, stirring makes its abundant hydrolysis, and the hydrolyzed solution filtered while hot is isolated oil reservoir, through washing, dehydration gets crude product oil
(2) crude product oil adds organic solvent, in-3 ℃～-20 ℃ following freezing and crystallizings, to be crystallized fully after, filter at low temperature, after oil strain steams and takes off organic solvent, the concentration of regulating tetraodontoxin in the oil strain is 0.01 μ g/ml～15 μ g/ml, adds stabilizing agent again and makes its mass percentage concentration in preparation reach 0.001%～0.2%, promptly gets globefish oil preparation.
Wherein said internal organs are globefish liver or globefish ovary; Described ammonium salt is selected from one or more in the following material: ammonium carbonate, ammonium sulfate, ammonium nitrate, ammonium chloride; Described weak base is ammonium hydroxide;
Described organic solvent is selected from one or more in the following material: normal hexane, acetone, isopropyl acetone, benzene, ethanol, and wherein thick oil is 1: 0.5～3 with the volume ratio of organic solvent;
Described stabilizing agent is selected from one or more in the following material: propyl gallate, tert-butylbenzene diphenol, butylated hydroxyarisol, Vc, Ve.
Between the various ammonium salts and the part by weight between the various stabilizing agent do not have special requirement.
Described globefish oil preparation when tetraodontoxin concentration is high in the puffer oil, adds medical oil; When tetraodontoxin concentration in the puffer oil is low, can add following one of them high puffer oil or the tetraodontoxin oil formulation of tetraodontoxin content.With the concentration adjustment of tetraodontoxin in the oil in the scope that requires.
The ammonium salt of described preparation usefulness, shared part by weight is 5%-20% in preparation solution.
Described medical oil is for Chinese Pharmacopoeia regulation injection oil or oral oil are Oleum Arachidis hypogaeae semen, Oleum Sesami, Oleum Glycines, Oleum Gossypii semen, almond oil, Oleum Camelliae and fish oil.
The ratio of described stabilizing agent shared quality in preparation is 0.001%～0.2%.
Globefish oil preparation of the present invention can be made capsule, Emulsion or suppository (work such as Zhuan Yue, " practical drug preparation technique ", People's Health Publisher, 1999, P263-276 according to the pharmaceutical preparation of routine; Lu Binzhu, " novel pharmaceutical formulation and new technique ", People's Health Publisher, 1998, P66-75; The Long Xiaoying work, " flow process pharmaceutics ", Chinese Medicine science and technology publishing house, 2003, P107-116).
Preparation of the present invention has the following advantages: it is tetraodontoxin that globefish oil preparation analgesia that 1, the present invention is clear and definite, drug rehabilitation main effectively becomes, and with tetraodontoxin as quality control standard; In addition, preparation of the present invention is rich in highly unsaturated fatty acid, has strengthened combined therapy effect and raise immunity.2, preparation of the present invention has significant analgesic activity, and curative effect of medication is definite, and characteristics are that onset is slow, and the prolongation of effect time is long, and still effective to morphine or dolantin tolerance addict, no addiction and toxic and side effects are safe.3, oral formulations of the present invention stores convenient, easy to carry, taking convenience, can be patient's medication and brings great convenience, alleviates patient's misery.4, preparation method of the present invention, the oil yield height, oil quality is good, and precipitate does not appear in steady quality, storage.
The specific embodiment
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.
Embodiment 1:
(1) get globefish liver 1000 grams, stripping and slicing adds 1 times of water, stirs 20～60 minutes, centrifugal filtration (filtrate is used for extracting tetraodontoxin) after the liver piece homogenate of filter back, adds 0.5 times of water, be stirred and heated to 30 ℃, add 10% ammonia, be transferred to pH=8, continue to be heated with stirring to 70 ℃, be incubated 30 minutes, add ammonium carbonate 80g, continue to stir, make its abundant hydrolysis, hydrolyzed solution is centrifugalize while hot, and oil, water, liver slag are collected respectively;
(2) washing: with 50 ℃ of hot water washing oil (oil is 1: 1 with the volume ratio of water) 2 times, fully stir, leave standstill 45 minutes after, make the profit layering, the collection oil reservoir;
(3) dehydration: slough W/O with the vacuum machine, get crude product oil;
(4) take off solid fat: crude product oil is after preliminary cooling, and the normal hexane that adds 0.5 times of oil volume mixes with oil, carries out crystallization under-8 ℃ condition, and crystallization back is fully filtered down at-8 ℃～-6 ℃.After the oil strain vacuum concentration reclaims organic solvent, add Oleum Arachidis hypogaeae semen (TTX concentration is higher than requirement content in the oil), regulating tetraodontoxin proportion in oil is 0.01 μ g/ml, again with propyl gallate, making its concentration in preparation is 0.2%, promptly gets globefish oil preparation.
Embodiment 2:
(1) after the globefish liver 1000 gram stripping and slicing homogenate, add 1.5 times of water, be stirred and heated to 40 ℃, divide secondary to add 12% ammonia, be transferred to pH=7, continue to be heated with stirring to 90 ℃, be incubated 40 minutes, add ammonium carbonate, 150 grams, continue to stir, make its abundant hydrolysis, hydrolyzed solution is centrifugalize while hot, and oil, water, liver slag are collected respectively;
(2) washing: with 60 ℃ of hot water washing oil (oil is 1: 1.5 with the volume ratio of water) 2 times, fully stir, leave standstill 35 minutes after, make the profit layering, the collection oil reservoir;
(3) dehydration: add 3% anhydrous CaCl in the oil
2Dehydration after the filtration, gets crude product oil;
(4) take off solid fat: crude product oil adds 1.5 times of amount acetone and mixes after preliminary cooling, carry out crystallization under-3 ℃ condition, and crystallization back is fully filtered under-11 ℃～-8 ℃ conditions.After the oil strain vacuum concentration reclaimed organic solvent, TTX concentration was 0.6 μ g/ml (tetraodontoxin is consistent with the concentration of preparation requirement) in the oil, and adding the tert-butylbenzene diphenol, to make its concentration in preparation be 0.1%, promptly gets globefish oil preparation.
Embodiment 3:
(1) globefish liver 1000 gram strippings and slicings add 1 times of water, stir 20～60 minutes, centrifugal filtration (filtrate is used for extracting tetraodontoxin), filter back liver piece adds 1 times of water, is stirred and heated to 50 ℃, add 13% ammonia, be transferred to pH=9, continue to be heated with stirring to 60 ℃, be incubated 45 minutes, add ammonium chloride 140 grams, continue to stir, make its abundant hydrolysis, hydrolyzed solution is centrifugalize while hot, and oil, water, liver slag are collected respectively;
(2) washing: with 65 ℃ of hot water washing oil (oil is 1: 2 with the volume ratio of water) 1 time, fully stir, leave standstill 20 minutes after, make the profit layering, the collection oil reservoir;
(3) dehydration: add 4% anhydrous CaCl in the oil
2Dehydration after the filtration, gets crude product oil;
(4) take off solid fat: crude product oil adds 2 times of amount isopropyl acetones and mixes after preliminary cooling, under-15 ℃ condition, carry out crystallization, crystallization back is fully filtered under-15 ℃～-10 ℃ conditions, after the oil strain vacuum concentration reclaims organic solvent, add the high puffer oil (TTX is lower than requirement concentration in the oil) of tetraodontoxin content, regulating tetraodontoxin proportion in oil is 5 μ g/ml, promptly gets globefish oil preparation.
Embodiment 4:
(1) globefish ovary 1000 gram strippings and slicings, add 3 times of water, stir 20～60 minutes post-heating to 60 ℃, add 7% ammonia, be transferred to pH=8.5, continue to be heated with stirring to 80 ℃, be incubated 60 minutes, add ammonium nitrate 210 grams, continue to stir, make its abundant hydrolysis, hydrolyzed solution is centrifugalize while hot, and oil, water, ovary slag are collected respectively;
(2) washing: with 65 ℃ of hot water washing oil (oil is 1: 1.5 with the volume ratio of water) 2 times, fully stir, leave standstill 20 minutes after, make the profit layering, the collection oil reservoir;
(3) dehydration: slough W/O with the vacuum machine, get crude product oil;
(4) take off solid fat: crude product oil adds 2 times of amount normal hexane and acetone mixed liquor (15% normal hexane, 85% aqueous acetone (moisture 1.4%)) after preliminary cooling, under-14 ℃ condition, carry out crystallization, crystallization back is fully filtered under-10 ℃～-5 ℃ conditions, after the oil strain vacuum concentration reclaims organic solvent, add tetraodontoxin oil formulation (TTX is lower than requirement concentration in the oil), tetraodontoxin concentration is 10 μ g/ml in the adjusting oil, it is 0.2% that the adding butylated hydroxyarisol makes its concentration in preparation, promptly gets globefish oil preparation.
Experimental example 1: puffer liver oil fatty acid composition:
The liver of worm stricture of vagina Fugu, yellowfin Fugu, the yellow Fugu of chrysanthemum, Fugu rubripes (Temmincket Schlegel) and artificial cultivation Fugu rubripes (Temmincket Schlegel) is gone out liver oil with extracted with diethyl ether, be prepared into the fatty acid methyl ester mixture respectively, with fatty acid methyl ester hybrid standard sample (Sigma company), carry out gas chromatography retention time and compare under identical conditions, quantitative approach adopts the peak area normalization method.Result's (seeing Table 1): the kind of the liver oil institute fatty acids of liver oil of four kinds of wild puffer fishes and artificial cultivation puffer fish is basic identical, though various fatty acid percentage composition is not quite similar, difference is very not big.Can record 18 kinds of content fatty acids, wherein saturated fatty acid content accounts for about 25% of fatty acid total amount, with C
16Content is the highest; Unsaturated fatty acid accounts for 71% of total fat amount, is 2.8 times of satisfied fatty acid, and wherein, eicosapentaenoic acid (EPA) and docosahexenoic acid (DHA) account for 9.3% and 17.3% of total fat amount.Polyenoic acid such as EPA and DHA is to constitute cell and component of organization, has special efficacy (anticarcinogen-C such as anti-angiocardiopathy, antiinflammatory, anticancer, enhancing immunity
20:5(Japan) openly speciallys permit communique, clear and 62-77319; Zhang Chaohui. " marine drug research and development ", the People's Health Publisher, 2003, P49).Do not find that in the content of puffer fatty acid oil unedible chemical compound exists.
The percentage ratio that five kinds of puffer liver oils of table 1 fatty acid is formed
| Fatty acid is formed | Wild Fugu | The artificial cultivation Fugu | |||
| The worm stricture of vagina | The chrysanthemum Huang | Yellowfin | Red fin | Red fin | |
| C 12:0 | 0.1 | 0.3 | 0.2 | 0.1 | - |
| C 14:0 | 1.8 | 2.5 | 3.4 | 2.7 | 2.5 |
| C 15:0 | 0.5 | 0.7 | 0.7 | 0.6 | 0.6 |
| C 16:0 | 16.7 | 17.1 | 15.5 | 15.7 | 16.6 |
| C 17:0 | 1.0 | 1.5 | 1.1 | 1.2 | 1.1 |
| C 18:0 | 4.7 | 4.3 | 5.5 | 4.0 | 4.6 |
| C 20:0 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 |
| C 16:1 | 15.8 | 14.7 | 10.8 | 13.9 | 15.3 |
| C 18:1 | 31.2 | 23.0 | 23.7 | 28.3 | 25.5 |
| C 18:2 | 1.2 | 1.0 | 1.9 | 1.5 | 1.5 |
| C 18:3/C 20:1 | 5.0 | 7.0 | 4.8 | 7.0 | 3.2 |
| C 18:4 | 0.9 | 0.6 | 1.1 | 1.0 | 0.8 |
| C 20:4/C 22 | 2.6 | 1.8 | 2.9 | 2.0 | 1.7 |
| C 20:5 | 2.6 | 2.2 | 2.7 | 2.8 | 3.2 |
| C 22:6 | 6.9 | 8.6 | 15.3 | 14.5 | 12.5 |
| Other | 3.9 | 5.5 | 5.8 | 3.9 | 4.2 |
Experimental example 2
The tumor that presses down of puffer liver oil is tested
Get 60 of white mice (18～20 gram), the strain of inoculation hepatocarcinoma tumor selected tumor strain white mice of the same size to be divided into experimental group and matched group, 10 every group after 3 days.Wherein experiment divides three groups, 1. globefish liver oil; 2. globefish oil preparation; 3. tetraodontoxin aqueous solution (containing tetraodontoxin 0.2 μ g/ml).Every day the lumbar injection secondary, each 0.2ml/ only, administration 10 days stopped administration after 3 days, dissected to get tumor and main internal organs are checked, experimental group and matched group tumor are heavily compared, and calculated suppression ratio.Experimental result (seeing Table 2): 1. globefish liver oil is 54% to the suppression ratio of tumor, and tumor killing effect is obvious, P＜0.05; 2. globefish oil preparation reaches 59% to the suppression ratio of tumor, and tumor killing effect is very obvious, P＜0.01; 3. tetraodontoxin aqueous solution group is to tumor body unrestraint effect.Illustrate that but the puffer liver oil exists the tumor component really, but be not tetraodontoxin; Pressing down the tumor component may be relevant with puffer liver oil camber unsaturated fatty acid.
Table 2 globefish liver extract presses down the tumor experiment
| Group | Dosage is only inferior | The tumor strain | Number of mice (only) | Average tumor heavy (gram) | Suppression ratio | The P value | ||
| Experimental group | Matched group | Experimental group | Matched group | |||||
| Globefish liver oil | 0.2 | Hepatoma | 10 | 10 | 1.1 | 2.4 | 54 | ＜0.05 |
| Globefish oil preparation | 0.2 | Hepatoma | 10 | 10 | 1.38 | 3.37 | 59 | ＜0.01 |
| Tetraodontoxin liquid (0.2 μ g/ml) | 0.2 | Hepatoma | 10 | 10 | 3.8 | 3.5 | Do not have | |
Experimental example 3
The mice hot plate analgesic experiment of puffer liver oil
Select the female mice of body weight 18～22g for use, 10 every group, elder generation measures the normal pain valve of each Mus before the administration.Lumbar injection puffer liver oil preparation and normal saline matched group (0.2ml/ only), measures 30,60,90,120 and 150 minutes mice bitterly valve once, every day, secondary was administered five times altogether.Experimental result: mice pain valve raising percentage rate is after the first administration: 29%, do not show obvious effect (P＞0.05) as yet; After the 2nd to 4 administration, mice pain valve improves that percentage rate is 33%, 34%, 49% respectively, (P＜0.05 and P＜0.01); After the last administration 48 hours, mice pain valve improves percentage rate and is: 47% (P＜0.01), and this explanation globefish oil preparation analgesic effect onset is slow, and behind the successive administration, analgesic effect can continue to rise, and analgesic activity is obvious, and analgesia duration is long.Before the matched group medicine with medicine after the no significant difference of pain valve reaction.
Experimental example 4
The screening experiment of puffer liver oil analgesic effective component
One of chromatographic silica gel glass column is housed, add puffer liver oil 10ml, when liver oil is reduced to the silica gel face, add the petroleum ether eluting earlier, divide bottle to collect eluent, every bottle of 50ml checks that eluent does not have till the component outflow, press Same Way again, successively add ether, petroleum ether-ethyl acetate (10: 1), petroleum ether-ethyl acetate (10: 1) and ethanol.Vapor away the solvent in the receiving flask, and carry out tracking and measuring in conjunction with mouse writhing analgesia method.As a result, collect in the fraction at petroleum ether-ethyl acetate (10: 1), have several bottles to detect analgesic activity, other collects fraction, does not have analgesic activity.
Be associated with the fraction of analgesic activity, pour in the separatory funnel, add acetic acid water (pH4.8) jolting, profit is fully mixed, leave standstill, collect water layer solution.Oil reservoir with the deionized water washing several times, merges aqueous solution so repeatedly, uses D152
#Weak-acid cation-exchange resin exchanges, and 8% acetic acid eluting is followed the tracks of toxicity with white mice, collects toxic fraction, concentrating under reduced pressure.Get concentrated solution and carry out thin layer chromatography, with the pure product contrast of tetraodontoxin, developing solvent is a n-butyl alcohol: acetic acid: water=4: 2: 2, the colour developing of weber reagent spray.The thin layer chromatography result, the pure product of tetraodontoxin are a pink garden speckle, Rf=0.48, sample also have a pink mottle at the Rf=0.48 place.So, assert that tentatively puffer liver oil analgesic effective ingredient is a tetraodontoxin.
Experimental example 5
The confirmatory experiment of puffer liver oil analgesic effective component
Adopt the white mice writhing method.White mice body weight 18～23g, the male and female dual-purpose, experiment divides two groups, 10 of every group of white mice.Experimental pharmacy: 1. puffer liver oil preparation, 2. Oleum Arachidis hypogaeae semen adds tetraodontoxin (tetraodontoxin content is 0.2 μ g/ml), with patent " preparation method of tetrodotoxin oil phase formulation " preparation (it is strong etc. that Huang causes, Chinese patent application number 200410080557.7).
Give mouse stomach (0.1ml/10g) with experimental pharmacy respectively, every day, secondary was administered three times altogether.Measure each Mus writhing response number before the first administration earlier, after the administration 3 hours, lumbar injection 0.6% acetic acid 0.2ml/ only write down mouse writhing number in 20 minutes, compares with writhing response before the administration.Result's (seeing Table 3) mouse writhing reaction suppression ratio is: 1. group is 9%; 2. group is that 24%, two group is not all showed obvious effect, P＞0.05; After the administration 3 hours for the third time, measure acetic acid and be respectively white mice writhing response suppression ratio: 90% and 85%, the obvious P of analgesic activity＜0.01.And two groups of administration relatively, and difference is not remarkable, P＞0.05.This result proves that puffer liver oil preparation analgesic effective ingredient is a tetraodontoxin.
Table 3 mouse writhing method is to the analgesic activity of puffer oil
| Group | Number of animals (only) | Turn round the body number before the medicine | Medicine is turned round the body number | Writhing response suppression ratio % for the third time | The P value | ||
| 3h behind the medicine | 3h behind the medicine for the third time | 3h behind the medicine | 3h behind the medicine | ||||
| Puffer liver oil preparation | 10 | 13.5 | 12.1 | 1.4 | 9 | 90 | ＜0.01 |
| Oleum Arachidis hypogaeae semen+TTX (TTX0.2 μ g/ml) | 10 | 15.4 | 11.7 | 2.3 | 24 | 85 | ＜0.01 |
Clinical trial analgesic effect
Cancer patient's 22 examples that admit to hospital, male's 16 examples, women's 6 examples, age, man 50 to 67 years old, woman 32 to 80 years old.Observing sick the kind altogether has: gastric cancer 4 examples, hepatocarcinoma 4 examples, pulmonary carcinoma 3 examples, rectal cancer 2 examples, Folium Nicotianae preparatum cancer 2 examples, colon cancer, thyroid carcinoma, cervical cancer, ovarian cancer, esophageal carcinoma, bladder cancer, each 1 example of lymphatic cancer.Cancer patient has other internal organs and lymphatic metastasis, and these patients mostly are mixed with persistence (majority) or paroxysmal (minority) pain.Dosage every day three times, 1～2 of each oral meal soft capsule (every contains one milliliter of Fugu ocellatus oil).It is to take medicine the result back about 3 hours that pain is observed: took medicine 1 day, pain relieving onset 4 examples account for 18.2%; 2 days onset 11 examples account for 50%; 3 days onset 5 examples account for 22.7%; 4 days not onset 2 examples account for 9%.From analgesic effect: no analgesic effect 2 examples account for 9.1%; Slight 1 example of alleviating accounts for 4.5%; Moderate pain relieving 10 examples account for 45.5%; Obviously pain relieving 5 examples account for 22.7%; Pain relieving 4 examples account for 18.2%, total effective rate 86.4% fully.The pain relieving characteristics are: onset is slow, but the pain relieving longer duration; To using narcosis analgesic tolerance addiction patient to still have analgesic activity.Its analgesia characteristics and zoopery be basically identical as a result.
Claims (5)
1, a kind of globefish oil preparation is characterized in that it is prepared by following method
(1) with homogenate after globefish liver or the globefish ovary stripping and slicing, add 0.5～3 times of water in liver or ovary weight ratio, be heated to 30～60 ℃ after, regulate pH value to 7～10, reheat to 60～90 ℃ are incubated 20～60 minutes, add 5%～20% ammonium salt by weight proportion, stirring makes its abundant hydrolysis, the hydrolyzed solution filtered while hot is isolated oil reservoir, through washing, dehydration gets crude product oil;
(2) crude product oil adds organic solvent, in-3 ℃～-20 ℃ following freezing and crystallizings, to be crystallized fully after, filter at low temperature, after oil strain steams and takes off organic solvent, the concentration of regulating tetraodontoxin in the oil strain is 0.01 μ g/ml～15 μ g/ml, adds stabilizing agent again and makes its mass percentage concentration in preparation reach 0.001%～0.2%, promptly gets globefish oil preparation.
2, preparation method as claimed in claim 1, it is characterized in that described ammonium salt is selected from one or more in the following material: ammonium carbonate, ammonium sulfate, ammonium nitrate, ammonium chloride, described weak base are ammonium hydroxide.
3, preparation method as claimed in claim 1 is characterized in that described organic solvent is selected from one or more in the following material: normal hexane, acetone, isopropyl acetone, benzene, ethanol.
4, preparation method as claimed in claim 1 is characterized in that the wherein thick oil and the volume ratio of organic solvent are 1: 0.5～3.
5, preparation method as claimed in claim 1 is characterized in that described stabilizing agent is selected from one or more in the following material: propyl gallate, tert-butylbenzene diphenol, butylated hydroxyarisol, Vc, Ve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004101039096A CN100340246C (en) | 2004-12-30 | 2004-12-30 | Globefish oil preparation and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004101039096A CN100340246C (en) | 2004-12-30 | 2004-12-30 | Globefish oil preparation and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1647800A CN1647800A (en) | 2005-08-03 |
| CN100340246C true CN100340246C (en) | 2007-10-03 |
Family
ID=34869707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004101039096A Active CN100340246C (en) | 2004-12-30 | 2004-12-30 | Globefish oil preparation and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100340246C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107047809A (en) * | 2017-03-31 | 2017-08-18 | 福州海汇生物科技实业有限公司 | A kind of fish oil preparation technology |
| CN107115298A (en) * | 2017-05-22 | 2017-09-01 | 黄海枫 | A kind of TTX emulsio olei jecoris piscis |
| CN108524522A (en) * | 2018-06-12 | 2018-09-14 | 中国水产科学研究院淡水渔业研究中心 | Application of the tetraodotoxin in preparing the drug for suppressing lung carcinoma cell to migrate and be proliferated |
| CN108524521A (en) * | 2018-06-12 | 2018-09-14 | 中国水产科学研究院淡水渔业研究中心 | Application of the tetraodotoxin in preparing the drug for inhibiting lung carcinoma cell or tumour to increase |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060342C (en) * | 1997-03-13 | 2001-01-10 | 辽阳鸿宇制药有限公司 | Application of liver oil of globefish in preparation of medicines for drug dependence |
| CN1072486C (en) * | 1996-09-24 | 2001-10-10 | 王维国 | Medicament for giving up narcotic drugs and stopping pain and its prepn. |
| CN1425666A (en) * | 2001-12-14 | 2003-06-25 | 上海华腾生物工程有限公司 | Method for extracting tetrodotoxin |
-
2004
- 2004-12-30 CN CNB2004101039096A patent/CN100340246C/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072486C (en) * | 1996-09-24 | 2001-10-10 | 王维国 | Medicament for giving up narcotic drugs and stopping pain and its prepn. |
| CN1060342C (en) * | 1997-03-13 | 2001-01-10 | 辽阳鸿宇制药有限公司 | Application of liver oil of globefish in preparation of medicines for drug dependence |
| CN1425666A (en) * | 2001-12-14 | 2003-06-25 | 上海华腾生物工程有限公司 | Method for extracting tetrodotoxin |
Non-Patent Citations (5)
| Title |
|---|
| 河?素（TTX）的分离、纯化及应用前景 李霞等，水产科技情报，第29卷第4期 2002 * |
| 河豚卵巢有效成分的提取及部分性质研究 余萍等，天然产物研究与开发，第11卷第5期 1999 * |
| 河豚毒素对钠通道的影响及其药理作用 邓建新，李晓蓓，余海民，实用医药杂志，第19卷第8期 2002 * |
| 河豚毒素的制取方法 曾漪青，科学养鱼，第5期 2004 * |
| 河豚肝油治疗尿布皮炎56例疗效观察 侯俊阁等，中国海洋药物，第7卷第1，2期 1988 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1647800A (en) | 2005-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1157773A (en) | Pharmaceutical and dietary compositions containing thioproline | |
| CN109942491B (en) | Anti-inflammatory and analgesic C in monkshood20Diterpene alkaloid and application thereof | |
| CN100340246C (en) | Globefish oil preparation and its preparing method | |
| RU2122408C1 (en) | Treatment with fatty acids | |
| CN1405314A (en) | Cryptoporus volvatus fermented product, and its preparation method and application | |
| CN101049360A (en) | Preparation of Chinese traditional medicine for treating gout disease, and application of extractive of Chinese feveruine | |
| CN1070226C (en) | Gallnut oil and its extraction process and application in pharmacy | |
| CN102423335A (en) | Medicine combination for treating impotence and premature ejaculation and preparation method thereof | |
| CN1186336C (en) | Prepn and application in preparing medicine of fraxinus general coumarin | |
| CN1748772A (en) | Acne removing preparation and new preparing method | |
| CN1316960C (en) | Compound mactra clam drip pill and its preparation method | |
| CN1720948A (en) | Dripping pills of lllicium henryi dripping pills and method for preparing the same | |
| CN1272290C (en) | Capejasmine cycloolefines ether terpene extract and its preparation method and use | |
| CN1122528C (en) | Composite safflower oil preparation and medicine containing it | |
| CN1435247A (en) | Chinese medicine preparation for treating lithiasis in urinary system and urethral infection, and preparing method thereof | |
| CN112279811A (en) | C20Diterpenoid alkaloids, their preparation and use for treating pain related diseases | |
| CN1287799C (en) | Bean curd fruit glycocide softcapsule | |
| CN1883499A (en) | Drip pills of mangiferin and preparation method thereof | |
| CN1119163C (en) | Anticancer composite medicine | |
| CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
| CN109985206A (en) | For preventing and treating the composition of alcoholic liver injury | |
| CN1167441C (en) | Xiangshen soft capsule and preparation process and use thereof | |
| CN1193516A (en) | Application of liver oil of globefish in preparation of medicines for drug dependence | |
| CN1742798A (en) | Wuhaiyingliu preparation and new preparing method | |
| CN1686432A (en) | Earthworm drip pill and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201125 Address after: No.2 Donggang Road, Haigang District, Qinhuangdao City, Hebei Province Patentee after: Hebei Academy of marine and Fishery Sciences (Hebei marine fishery ecological environment monitoring station) Address before: 066002 5-5-8 mailbox in construction of Hebei City, Qinhuangdao Province Patentee before: Huang Zhiqiang |